ERIS Lifescience

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406M01024
  • NSEID: ERIS
  • BSEID: 540596
INR
1,319.50
-8.4 (-0.63%)
BSENSE

Nov 20

BSE+NSE Vol: 35.84 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,319.50",
    "chg": -8.4,
    "chgp": "-0.63%",
    "dir": -1,
    "prev_price": "1,327.90",
    "mcapval": "18,356.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE406M01024",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "35.84 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-by-marketsmojo-4270019",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ERISLifescience_mojoScore_4270019.png",
        "date": "2026-11-21 10:10:33",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-4257297",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ERISLifescience_mojoScore_4257297.png",
        "date": "2026-11-10 10:10:30",
        "description": "ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 27 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "ERIS Lifesciences Gains 6.25%: Valuation and Technical Shifts Shape Weekly Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/eris-lifesciences-gains-625-valuation-and-technical-shifts-shape-weekly-momentum-4255221",
        "imagepath": "",
        "date": "2026-11-07 13:04:35",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> Stock opens at Rs.1,163.25, Sensex up 1.57%</p>\n                    <p><strong>3 Nov:</strong> Strong volume surge accompanies 1.22% price rise</p>\n                    <p><strong>4 Nov:</strong> Valuation shift noted as stock gains 3.40%</p>\n                    <p><strong>5 Nov:</strong> Technical momentum shifts amid mixed signals</p>\n                    <p><strong>6 Nov:</strong> Week closes at Rs.1,232.05, up 0.17% on day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,159.60</div></div>\n                    <div class=\"stat-item\"><di..."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Amid Mixed Market Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-amid-mixed-market-returns-4251330",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ERISLifescience_valuationdot_4251330.png",
        "date": "2026-11-05 08:03:03",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating as of late October 2026. This change reflects evolving market perceptions amid a challenging sector environment and relative to its pharmaceutical peers. Despite a recent 3.4% intraday price gain, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook from investors."
      },
      {
        "title": "ERIS Lifesciences Gains 5.64%: Four Key Factors Driving the Week’s Volatility",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/eris-lifesciences-gains-564-four-key-factors-driving-the-weeks-volatility-4245744",
        "imagepath": "",
        "date": "2026-10-31 14:00:38",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>26 Oct:</strong> Stock hits 52-week low at Rs.1,069 amid market pressure</p>\n                    <p><strong>27 Oct:</strong> Intraday high surge of 7.43% to Rs.1,193.05</p>\n                    <p><strong>28 Oct:</strong> Quality grade downgraded from good to average</p>\n                    <p><strong>28 Oct:</strong> Valuation grade upgraded from very attractive to attractive</p>\n                    <p><strong>30 Oct:</strong> Week closes at Rs.1,159.60, up 5.64% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,097.65</div></div>\n          ..."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-4244561",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ERISLifescience_mojoScore_4244561.png",
        "date": "2026-10-30 10:10:48",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 October 2026. However, the analysis below reflects the stock's current position as of 30 October 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective."
      },
      {
        "title": "ERIS Lifesciences Ltd: Valuation Shift Enhances Price Attractiveness Amid Mixed Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shift-enhances-price-attractiveness-amid-mixed-returns-4241369",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ERISLifescience_valuationdot_4241369.png",
        "date": "2026-10-28 08:00:57",
        "description": "ERIS Lifesciences Ltd has witnessed a notable improvement in its valuation parameters, prompting a revision in its investment grade from Sell to Hold. With its price-to-earnings (P/E) ratio now at 21.83 and price-to-book value (P/BV) at 3.98, the pharmaceutical and biotechnology company is increasingly viewed as an attractive proposition relative to its historical averages and peer group benchmarks."
      },
      {
        "title": "ERIS Lifesciences Ltd Quality Grade Downgrade: A Detailed Analysis of Business Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/eris-lifesciences-ltd-quality-grade-downgrade-a-detailed-analysis-of-business-fundamentals-4241280",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ERISLifescience_qualitydot_4241280.png",
        "date": "2026-10-28 08:00:06",
        "description": "ERIS Lifesciences Ltd has recently seen its quality grade downgraded from good to average, reflecting shifts in key business fundamentals. Despite a strong market cap and a recent positive day change of 8.38%, the company’s underlying financial metrics reveal a mixed picture, with some improvements overshadowed by emerging concerns in profitability consistency and leverage ratios."
      },
      {
        "title": "Markets Rally, But ERIS Lifesciences Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/eris-lifesciences-ltd-falls-to-52-week-low-amid-market-downturn-4234376",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ERISLifescience_priceRelatedfactors_4234376.png",
        "date": "2026-10-22 15:41:02",
        "description": ""
      }
    ],
    "total": 68,
    "sid": "1002771",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "13-Nov-2026",
      "details": "as attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Nov-2026",
      "details": "as attached",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "04-Nov-2026",
      "details": "as attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>721%</strong> dividend, ex-date: 29 May 26",
          "dt": "2026-05-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

13-Nov-2026 | Source : BSE

as attached

Announcement under Regulation 30 (LODR)-Newspaper Publication

06-Nov-2026 | Source : BSE

as attached

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

04-Nov-2026 | Source : BSE

as attached

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

ERIS Lifesciences Ltd has declared 721% dividend, ex-date: 29 May 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available